Drugs / 2-hydroxybenzoylaminooctanoate
2-hydroxybenzoylaminooctanoate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04781725 | Mar 2021 → Mar 2022 | breast cancer | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-hydroxybenzoylaminooctanoate | “INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗ |
| Known as | 2-hydroxybenzoylaminooctanoate (SAHO) | “2-hydroxybenzoylaminooctanoate (SAHO)” NCT04781725 ↗ |
| Known as | SHAO | “INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗ |
| Known as | SHAO-FA | “INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗ |